Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $30.00 Average Target Price from Analysts

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) have earned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $30.00.

Several equities analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group assumed coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $23.00 price target on the stock. HC Wainwright raised shares of Avalo Therapeutics from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research report on Monday, June 2nd. Finally, Stifel Nicolaus assumed coverage on shares of Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 price target on the stock.

Avalo Therapeutics Price Performance

AVTX stock opened at $5.01 on Thursday. The company’s 50-day moving average is $4.44 and its 200-day moving average is $6.20. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Monday, May 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.18). As a group, equities analysts predict that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its stake in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock valued at $31,000 after buying an additional 3,754 shares during the last quarter. ADAR1 Capital Management LLC purchased a new stake in Avalo Therapeutics in the 1st quarter valued at about $80,000. Marshall Wace LLP purchased a new stake in Avalo Therapeutics in the 4th quarter valued at about $114,000. Walleye Capital LLC purchased a new stake in Avalo Therapeutics in the 4th quarter valued at about $145,000. Finally, Northern Trust Corp purchased a new stake in Avalo Therapeutics in the 4th quarter valued at about $168,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.